Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tetrahydrofolic acid (also known as tetrahydrofolate or THFA) is a biologically active derivative of folic acid and serves as the main active metabolite of dietary folate. It is produced from dihydrofolic acid by the enzyme dihydrofolate reductase and can be further converted into 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase. Tetrahydrofolic acid functions as a coenzyme in numerous metabolic reactions, particularly those involved in the synthesis of amino acids and nucleic acids. It acts as a carrier for single-carbon groups (such as methyl, methylene, formyl), which are essential for DNA synthesis and other biosynthetic processes. Deficiency in tetrahydrofolic acid can lead to impaired cell division and megaloblastic anemia. Clinically, it is used for nutritional supplementation to treat or prevent folate deficiency states such as megaloblastic anemia and during pregnancy to prevent neural tube defects[1][2][3][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tetrahydrofolic acid.